Eplontersen sodium
As of the edition of 20 October 2026, Eplontersen sodium is an oligonucleotide: marketed, first approved in 2023 (US); acts on TTR; US protection ends in 2034.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2024
- Kind
- Oligonucleotide
- Brand name
- Wainua (autoinjector)
- First approved
- 21 December 2023 (US)
- Approvals on record
- 3 in 2 regions
- Holder of the most recent approval
- AstraZeneca
US protection
US protection ends in 2034.
The last listed US drug-substance patent ends in 2034. The application that gives this date is held by AstraZeneca.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product9 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 9 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Eplontersen sodium.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TTR | Transthyretin | P02766 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AstraZeneca | Originator | 2023 to now |